论文部分内容阅读
目的:初步探讨FLAG方案在初治急性单核细胞白血病(M5)诱导化疗中的临床疗效和不良反应。方法:10例初治M5患者,采用FLAG方案诱导化疗,具体用法为氟达拉滨(Flud)30mg.m-2.d-1,持续静脉滴注30min,第1～5天;阿糖胞苷(Ara-C)1g.m-2.d-1,Flud结束后4h开始,持续静脉滴注4h,第1～5天;粒细胞集落刺激因子(G-CSF)5μg.kg-1.d-1,皮下注射,第0～5天。以完全缓解率(CR)和有效率及不良反应作为观察指标。结果:1个疗程FLAG方案诱导化疗患者CR率为80%,有效率为90%。化疗的不良反应主要为骨髓抑制和粒细胞缺乏所致的感染,未见严重的非血液系统不良反应。结论:FLAG方案诱导化疗初治急性单核细胞白血病患者具有较高的CR率,不良反应可耐受。
Objective: To investigate the clinical efficacy and adverse reactions of FLAG regimen in the induction of chemotherapy-naive acute monocytic leukemia (M5). Methods: Ten cases of newly diagnosed M5 patients were treated with FLAG chemotherapy. The specific use was Flud 30mg.m-2.d-1, continuous intravenous infusion of 30min, 1st to 5th day; Glycosides (Ara-C) 1g.m-2.d-1, Flud 4h after the start, continuous intravenous infusion of 4h, 1 to 5 days; granulocyte colony stimulating factor (G-CSF) 5μg.kg-1. d-1, subcutaneous injection, the first 0 to 5 days. Complete response rate (CR) and efficiency and adverse reactions as indicators. Results: One course of chemotherapy induced by FLAG regimen was 80% and the effective rate was 90%. Adverse reactions to chemotherapy were mainly due to myelosuppression and agranulocytosis, and no serious non-hematological adverse reactions. CONCLUSION: FLAG regimen induces chemotherapy in newly diagnosed acute monocytic leukemia patients with high CR rate and adverse reactions.